Cytokinetics Gestione

Gestione criteri di controllo 2/4

Cytokinetics Il CEO è Robert Blum, nominato in Feb2006, e ha un mandato di 18.75 anni. la retribuzione annua totale è $ 8.75M, composta da 9% di stipendio e 91% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.23% delle azioni della società, per un valore di € 13.54M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.6 anni e 11.8 anni.

Informazioni chiave

Robert Blum

Amministratore delegato

US$8.8m

Compenso totale

Percentuale dello stipendio del CEO	9.0%
Mandato del CEO	18.8yrs
Proprietà del CEO	0.2%
Durata media del management	3.6yrs
Durata media del Consiglio di amministrazione	11.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Robert Blum rispetto agli utili di Cytokinetics?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-US$576m
Jun 30 2024	n/a	n/a	-US$545m
Mar 31 2024	n/a	n/a	-US$531m
Dec 31 2023	US$9m	US$790k	-US$526m
Sep 30 2023	n/a	n/a	-US$527m
Jun 30 2023	n/a	n/a	-US$540m
Mar 31 2023	n/a	n/a	-US$431m
Dec 31 2022	US$9m	US$742k	-US$389m
Sep 30 2022	n/a	n/a	-US$282m
Jun 30 2022	n/a	n/a	-US$216m
Mar 31 2022	n/a	n/a	-US$258m
Dec 31 2021	US$6m	US$709k	-US$215m
Sep 30 2021	n/a	n/a	-US$229m
Jun 30 2021	n/a	n/a	-US$156m
Mar 31 2021	n/a	n/a	-US$135m
Dec 31 2020	US$5m	US$682k	-US$127m
Sep 30 2020	n/a	n/a	-US$114m
Jun 30 2020	n/a	n/a	-US$140m
Mar 31 2020	n/a	n/a	-US$132m
Dec 31 2019	US$3m	US$656k	-US$122m
Sep 30 2019	n/a	n/a	-US$118m
Jun 30 2019	n/a	n/a	-US$110m
Mar 31 2019	n/a	n/a	-US$105m
Dec 31 2018	US$3m	US$630k	-US$106m
Sep 30 2018	n/a	n/a	-US$120m
Jun 30 2018	n/a	n/a	-US$131m
Mar 31 2018	n/a	n/a	-US$132m
Dec 31 2017	US$3m	US$612k	-US$128m

Compensazione vs Mercato: La retribuzione totale di Robert ($USD 8.75M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 3.51M ).

Compensazione vs guadagni: La retribuzione di Robert è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Robert Blum (60 yo)

18.8yrs

Mandato

US$8,751,057

Compensazione

Mr. Robert I. Blum has been Chief Executive Officer, President and Director of Cytokinetics, Incorporated since January 22, 2007 and served as its Principal Financial Officer until May 08, 2024. Mr. Blum p...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Robert Blum	CEO, President & Director	18.8yrs	US$8.75m	0.23% € 13.5m
Robert Wong	VP & Chief Accounting Officer	5.5yrs	US$1.04m	0.0063% € 369.7k
Fady Malik	Executive Vice President of Research & Development	12.4yrs	US$4.44m	0.053% € 3.1m
Andrew Callos	Executive VP & Chief Commercial Officer	3.7yrs	US$3.20m	0.021% € 1.2m
James Spudich	Co-Founder & Member of Scientific Advisory Board	27.3yrs	US$21.94k	Nessun dato
Sung Lee	Executive VP & CFO	less than a year	Nessun dato	Nessun dato
Jeff Lotz	Vice President of Sales & Operations	3.2yrs	Nessun dato	Nessun dato
Matt Yang	Vice President of Corporate Finance and Financial Planning & Analysis	less than a year	Nessun dato	Nessun dato
Steven Cook	Senior Vice President of Global Supply Chain Operations & Technical Operations	no data	Nessun dato	Nessun dato
Kari Loeser	VP & Chief Compliance Officer	3yrs	Nessun dato	Nessun dato
John Faurescu	VP, Associate General Counsel & Corporate Secretary	no data	Nessun dato	Nessun dato
Scott Jordan	Senior Vice President of Global Marketing & Commercial Strategy	3.5yrs	Nessun dato	Nessun dato

3.6yrs

Durata media

60yo

Età media

Gestione esperta: Il team dirigenziale di KK3A è considerato esperto (durata media dell'incarico 3.6 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Robert Blum	CEO, President & Director	17.8yrs	US$8.75m	0.23% € 13.5m
James Spudich	Co-Founder & Member of Scientific Advisory Board	no data	US$21.94k	Nessun dato
B. Parshall	Independent Director	11.8yrs	US$529.02k	0.013% € 742.3k
James H. Sabry	Co-Founder & Chairman of Scientific Advisory Board	16.6yrs	US$41.50k	Nessun dato
Nancy Wysenski	Independent Director	4yrs	US$519.02k	0.015% € 860.3k
John Henderson	Independent Chairman	15.8yrs	US$559.02k	0.028% € 1.6m
John Lowe	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Thomas Pollard	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
David Morgans	Member of Scientific Advisory Board	8.3yrs	US$942.23k	Nessun dato
Lawrence S. Goldstein	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
John Solaro	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Muna Bhanji	Independent Director	3.8yrs	US$509.02k	0.010% € 595.1k

11.8yrs

Durata media

68yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di KK3A è composto da personale esperto e esperto (durata media dell'incarico 11.8 anni).

Cytokinetics Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

CEO, President & Director recently sold €580k worth of stock

CEO, President & Director recently sold €1.1m worth of stock

VP & Chief Accounting Officer recently sold €584k worth of stock

Cytokinetics, Incorporated Announces Resignation of Sandford D. Smith as Board of Directors

Cytokinetics, Incorporated Appoints Sung H. Lee as Executive Vice President, Effective as of May 8, 2024

Cytokinetics, Incorporated, Annual General Meeting, May 15, 2024

Recent updates

Cytokinetics, Incorporated Presents Additional Data from GALACTIC-HF At the American Heart Association Scientific Sessions 2024

Cytokinetics, Incorporated Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy At the American Heart Association Scientific Sessions 2024

Cytokinetics, Incorporated Presents Additional Data from GALACTIC-HF At the American Heart Association Scientific Sessions 2024

Cytokinetics, Incorporated Announces Initiation of Phase 1 Clinical Study of CK-4015089

New major risk - Negative shareholders equity

Third quarter 2024 earnings released: US$1.36 loss per share (vs US$1.35 loss in 3Q 2023)

Cytokinetics, Incorporated to Report Q3, 2024 Results on Nov 06, 2024

Cytokinetics Presents Additional Data from EQUOIA-HCM At the HCMS Scientific Sessions

Cytokinetics, Incorporated Presents Additional Data from SEQUOIA-HCM at the European Society of Cardiology Congress 2024

Second quarter 2024 earnings released: US$1.31 loss per share (vs US$1.34 loss in 2Q 2023)

New minor risk - Share price stability

Cytokinetics, Incorporated to Report Q2, 2024 Results on Aug 08, 2024

CEO, President & Director recently sold €580k worth of stock

CEO, President & Director recently sold €1.1m worth of stock

Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants

New minor risk - Share price stability

VP & Chief Accounting Officer recently sold €584k worth of stock

New minor risk - Insider selling

Cytokinetics, Incorporated announced that it has received $49.999992 million in funding from Royalty Pharma Development Funding, LLC

Cytokinetics, Incorporated has completed a Follow-on Equity Offering in the amount of $500.000022 million.

Cytokinetics, Incorporated Announces Resignation of Sandford D. Smith as Board of Directors

First quarter 2024 earnings released: US$1.33 loss per share (vs US$1.38 loss in 1Q 2023)

Cytokinetics, Incorporated Announces CEDAR-HCM Is Open to Enrollment

Cytokinetics, Incorporated Appoints Sung H. Lee as Executive Vice President, Effective as of May 8, 2024

Cytokinetics, Incorporated to Report Q1, 2024 Results on May 08, 2024

Cytokinetics, Incorporated, Annual General Meeting, May 15, 2024

Cytokinetics Presents Additional 48-Week Data from Forest-Hcm, the Open Label Extension Clinical Study of Aficamten, At the American College of Cardiology 73rd Annual Scientific Session

Cytokinetics, Incorporated Provides Revenue Guidance for 2024

Full year 2023 earnings released: US$5.45 loss per share (vs US$4.33 loss in FY 2022)

New major risk - Revenue and earnings growth

Cytokinetics, Incorporated to Report Q4, 2023 Results on Feb 27, 2024

Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw as Chief Financial Officer, Effective February 23, 2024

Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw, Senior Vice President, Effective February 23, 2024

Novartis Pursuit of Cytokinetics Reportedly Cools

Novartis Reportedly in Advanced Talks to Buy Cytokinetics

Cytokinetics, Incorporated Announces Positive Results from Sequoia-Hcm, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy

Now 20% undervalued

Cytokinetics Presents Results from COURAGE-ALS At the 34th International Symposium on ALS/MND

Insufficient new directors

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$1.35 loss per share (vs US$1.52 loss in 3Q 2022)

Cytokinetics, Incorporated to Report Q3, 2023 Results on Nov 02, 2023

Cytokinetics, Incorporated Provides Update on Cardiac Myosin Inhibitor Programs and Plans to Build a Specialty Cardiology Franchise at Virtual Investor & Analyst Day

New minor risk - Share price stability

Cytokinetics, Incorporated Presents Baseline Characteristics from SEQUOIA-HCM at the HCM Society

Second quarter 2023 earnings released: US$1.34 loss per share (vs US$0.23 loss in 2Q 2022)

Cytokinetics, Incorporated to Report Q2, 2023 Results on Aug 03, 2023

Cytokinetics, Incorporated Presents New Data in Patients with Non-Obstructive Hcm from Cohort 4 of Redwood-Hcm in Late-Breaking Clinical Trial Session At the European Society of Cardiology Heart Failure 2023 Congress

Cytokinetics, Incorporated Announces Initiation of Phase 1 Clinical Study of CK-4021586

First quarter 2023 earnings released: US$1.38 loss per share (vs US$1.05 loss in 1Q 2022)

Now 22% undervalued after recent price drop

Now 20% undervalued after recent price drop

Full year 2022 earnings released: US$4.33 loss per share (vs US$2.80 loss in FY 2021)

Cytokinetics, Incorporated to Report Q4, 2022 Results on Mar 01, 2023

Cytokinetics, Incorporated Announces Outcome of FDA Advisory Committee Vote On Omecamtiv Mecarbil

Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3828136

VP & Chief Accounting Officer recently sold €83k worth of stock

Cytokinetics, Incorporated Presents New Data at the American Heart Association Scientific Sessions 2022

Third quarter 2022 earnings released: US$1.52 loss per share (vs US$0.95 loss in 3Q 2021)

Cytokinetics, Incorporated to Report Q3, 2022 Results on Nov 03, 2022

Cytokinetics, Incorporated Announces Continuation of COURAGE-ALS Following First Interim Analysis

Cytokinetics, Incorporated Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HCM Society Scientific Sessions

Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.86 loss in 2Q 2021)

Cytokinetics and The ALS Association Announce Release of Updated PRO-ACT Database Including Data From Cytokinetics' Completed ALS Clinical Trials

Cytokinetics, Incorporated to Report Q2, 2022 Results on Aug 04, 2022

Cytokinetics, Incorporated Provides Update on New Drug Application

Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing COURAGE-ALS

Cytokinetics, Incorporated Announces Additional Data from Redwood-HCM Presented At the American Society of Echocardiography 33Rd Annual Scientific Sessions

First quarter 2022 earnings released: US$1.05 loss per share (vs US$0.66 loss in 1Q 2021)